ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1402

Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease

Saviana Gandolfo1, Flavia Riccio2, Mariachiara Visconti3, Corrado Parlati3, Nicola Della Rossa4, Enrico Tirri5 and Francesco Ciccia3, 1Rheumatology Unit, Ospedale del mare, Naples, Naples, Naples, Italy, 2Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Napoli, Italy, 3Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, 4Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, 5Rheumatology Unit, Ospedale del mare, Naples, Italy, Naples, Italy

Meeting: ACR Convergence 2025

Keywords: Fatigue, Outcome measures, Patient reported outcomes, quality of life, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Fatigue is one of the most frequent, debilitating and impactful symptoms for patients with Sjögren’s Disease (SjD), and one of the most challenging to measure. To date, there are no PROs fully capturing fatigue as experienced by patients in their daily lives.The purpose of this study was to define a new PRO for assessing fatigue and its impact on the quality of life of patients with SjD, based on lived experiences and their own definitions of fatigue.

Methods: Inspired by an essay written by a patient with SjD on the Sjögren’s Foundation website (1), a new fatigue questionnaire, including 15 distinct types of fatigue (basic, rebound, sudden, weather-related, molten lead phenomenon, tired-wired, flare-related, fatigue related to other physical causes, fatigue-related concentration impairment, stress/distress/anxiety/depression SDAD-related fatigue, not sleeping well fatigue, normal aging fatigue, chronic illness fatigue, fatigue from trying to keep up with family and friends without a chronic illness, and doctor fatigue) was created and administered to SjD patients. Correlations with ESSPRI, ESSDAI, clinical and laboratory parameters were analyzed.

Results: 90 consecutive patients (female 93.4%) fulfilling SjD ACR/EULAR 2016 criteria, mean age 57.1 years (range 21–82), completed the questionnaire. The most frequently reported types of fatigue were SDAD(88.9%), basic (86.7%), and rebound (86.7%), while the least reported was weather-related (60%). Among all types, the SDAD had the highest impact on quality of life (mean impact score 82.8%). Males more frequently reported SDAD (100%), doctor fatigue (100%), and not sleeping well (83.4%), while females reported rebound (89.3%), basic (88.1%), and SDAD (88.1%). Younger and older patients reported basic fatigue more frequently (85.7% and 100%, respectively), compared to middle-aged groups, reporting SDAD(36–59 years: 92.1%; 60–70 years: 87.5%). Rebound was the only type correlating with disease duration (r=0.22, p0.03). Although SDAD was the most frequently reported and impacting type, it did not significantly correlate with ESSPRI, whereas strong correlations were observed between ESSPRI and other types, particularly basic (r=0.54, p< 0.0001) and rebound (r=0.50, p< 0.0001). Certain types of fatigue strongly correlated with each other, such as basic and rebound (r=0.90, p< 0.0001), or specifically with other symptoms, such as flare-related and VASglobal pain (r=0.41, p< 0.0001). No correlations were observed with ESSDAI or lab parameters, except for the molten lead phenomenon with CRP (r=0.55, p0.007).

Conclusion: This novel SjD fatigue questionnaire captures aspects of real-life fatigue previously underrepresented in existing PROs, and reveals heterogeneity in patient experiences. These differences, along with the clustering of fatigue types and symptoms, underscore the importance of a fatigue-based patient profiling, with potential implications for pathophysiological understanding and personalized treatment. Ongoing efforts focus on validating the questionnaire, stratifying patients based on fatigue, and establishing its role as an outcome measure.1.https://sjogrens.org/blog/2019/13-types-of-sjogrens-fatigue


Disclosures: S. Gandolfo: None; F. Riccio: None; M. Visconti: None; C. Parlati: None; N. Della Rossa: None; E. Tirri: None; F. Ciccia: None.

To cite this abstract in AMA style:

Gandolfo S, Riccio F, Visconti M, Parlati C, Della Rossa N, Tirri E, Ciccia F. Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/understanding-fatigue-through-patients-eyes-development-of-a-novel-questionnaire-capturing-the-complexity-of-real-life-fatigue-in-sjogrens-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/understanding-fatigue-through-patients-eyes-development-of-a-novel-questionnaire-capturing-the-complexity-of-real-life-fatigue-in-sjogrens-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology